Motif's Wireless Depression Implant Cleared for First Human Trial
· TexaHub · Biotech & Med-Tech
The FDA has approved an early feasibility study of Motif Neurotech's blueberry-sized, skull-mounted stimulator for treatment-resistant depression, a small trial focused first on safety.
What the FDA approved
Houston-based Motif Neurotech said on 27 April that the FDA had approved its request to begin the RESONATE early feasibility study of the Motif XCS System, whose implant is called DOT, in adults with treatment-resistant depression who have failed two or more medications [1][4]. Medical Device Network reported the approval as an investigational device exemption [5]. The study's primary endpoint is safety over 12 months after implantation, with depression symptoms, quality of life, anxiety and cognitive function as secondary measures [1].
The trial will run at up to eight institutions, including Baylor College of Medicine, Mass General Brigham, Emory Healthcare, UT Health Houston, the University of Iowa, University of Utah Health and New York University [1]. Popular Science reported that it will involve about 10 participants [4].
How the device differs
DOT is roughly the size of a blueberry and is wirelessly powered [1]. According to Rice University, where the technology originated in the Robinson and Yang labs, it sits in the skull above the dura without touching the brain [2]. Motif describes implantation as a 20-minute outpatient procedure [1], while Popular Science gave the figure as 20 to 30 minutes [4]. Popular Science also reported that stimulation is driven by a specially designed baseball cap, and that patients could potentially wear it for several 10- to 20-minute sessions a day [4].
"The goal for this technology is that it would be the mental health equivalent of a continuous glucose monitor for diabetes," said Jacob Robinson, Motif's chief executive and a Rice professor [2]. Sameer Sheth of Baylor, the study's principal investigator, said treatment-resistant depression is "one of the leading causes of disability and suicide in the U.S. and worldwide" [1][2].
Development has been funded by ARPA-H, DARPA and NIH [2]. On 30 April Motif also signed a multi-year supply agreement with MintNeuro, an Imperial College London spinout that designs low-power neural sensing and stimulation chips [3]. That release said Motif was founded in 2022 and has raised more than $30 million in venture capital [3].
Why it matters
Medical Device Network put the number of Americans with treatment-resistant depression at nearly 3 million, and noted competing approaches: Abbott began a pivotal deep brain stimulation trial in March 2025, and Flow Neuroscience's FL-100 transcranial direct current stimulation headset gained FDA clearance in December 2025 [5].
Motif sits between those two: more invasive than a headset, much less invasive than deep brain stimulation. An early feasibility study with around ten patients is designed to show the device is safe, not that it works, so efficacy claims should wait. The questions for this trial are whether a minimally invasive implant with at-home dosing holds up over a year, and whether patients will keep using it.
Sources
[1] Motif Neurotech Receives FDA Approval to Begin First Clinical Trial of its Therapeutic BCI for Treatment-Resistant Depression — Business Wire, 27 Apr 2026
[2] Brain-computer interface based on Rice research wins FDA approval for first clinical trial — Rice University, 28 Apr 2026
[3] MintNeuro and Motif Neurotech Partner to Advance Miniature Brain-Computer Interface Therapy for Mental Health — PR Newswire, 30 Apr 2026
[4] A brain implant to treat depression gets FDA greenlight to start trials — Popular Science, 1 May 2026
[5] Motif Neurotech secures FDA IDE to initiate depression implant study — Medical Device Network, 27 Apr 2026